|
Spain-FE-FE Azienda Directories
|
Azienda News:
- List of 43 Hemophilia A Medications Compared - Drugs. com
Expanded Access is a potential pathway for a patient with a serious or immediately life-threatening disease or condition to gain access to an investigational medical product (drug, biologic, or medical device) for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available
- Hemophilia Therapies - Rare Disease Advisor
Koāte ® (antihemophilic factor [human]), also known as Koāte-DVI, is a human plasma-derived FVIII indicated for the treatment and prevention of bleeding episodes in patients with hemophilia A Initially approved in the US in 1974, the processing methods have been updated over the years to make the product safer from viral contamination
- Acquired Hemophilia Treatment Management - Medscape
Recombinant antihemophilic factor, porcine sequence Historically, porcine factor VIII has provided a good effect A porcine sequence recombinant FVIII (rpFVIII; Obizur) was approved by the US Food and Drug Administration (FDA) in 2014 for treatment of bleeding episodes in adults with acquired hemophilia
- Treatment Options in Hemophilia - PMC - PubMed Central (PMC)
Long-acting coagulation factor drugs can lengthen the time between treatments or increase coagulation factor levels New treatment options are based on new mechanisms of action and can be administered subcutaneously, sometimes with an extended half-life and a broad spectrum of application for hemophilia A, hemophilia B, and inhibitor hemophilia
- List of Treatments for Hemophilia | MyHemophiliaTeam
Jivi (Antihemophilic Factor [Recombinant] Pegylated-Aucl) Overview Jivi is a recombinant antihemophilic factor approved by the U S Food and Drug Administration (FDA) for the treatment and management of hemophilia A (congenital factor VIII [8] deficiency) in previously treated… read more
- Factor VIII replacement therapy options in hemophilia A - Altuviiio. com
The two other treatment options include non-factor replacement therapies—a factor VIII mimetic that targets different points in the clotting process rather than simply replacing the missing factor VIII and gene therapy— a one-time treatment that works by replacing a missing or faulty gene to create factor VIII [antihemophilic factor
- Proper Dosing, Bleeding Awareness Are Essential Roles for Pharmacists . . .
Treatment options for hemophilia include Eloctate, Altuviiio, and Alprolix, each with unique benefits and considerations for patient-specific factors Eloctate (antihemophilic factor [recombinant], Fc fusion protein; Sanofi) was approved over a decade ago for the control and prevention of bleeding episodes, routine prophylaxis, and surgical
- AHF (Antihemophilic Factor): Uses Side Effects - Cleveland Clinic
AHF (antihemophilic factor) is a medication that prevents or manages bleeding if you have hemophilia A This condition keeps your blood from clotting as it should so you bleed more than expected A healthcare provider will usually give you this injection in a hospital or clinic setting
- Hemophilia treatment options | Hemophilia News Today
Factor replacement therapies contain a working version of a clotting factor that can replace the missing protein in people with hemophilia types A or B These treatments, which are administered intravenously, or directly into the bloodstream, may be given routinely as prophylaxis to prevent and lower the risk of bleeds, or used in an on-demand
|
|